ReviewFrontiers in immunology2026
The immunometabolic axis of sepsis-related myocardial injury: macrophage reprogramming as a central mechanism and therapeutic target.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-related myocardial injury (SRMI) is a major cause of death in critically ill patients, with pathogenesis extending beyond inflammation to encompass dysregulated immunometabolic crosstalk. This review elucidates macrophage metabolic reprogramming as a central mechanism driving SRMI, detailing how a shift to aerobic glycolysis fuels pro-inflammatory responses, while oxidative phosphorylation supports reparative functions. We emphasize that metabolites like succinate, itaconate, and lactate act as potent signaling molecules, orchestrating epigenetic changes and inflammatory pathways. Furthermore, we deconstruct the critical immunometabolic dialogue mediated by extracellular vesicles (EVs) and signaling cascades among macrophages, cardiomyocytes, and endothelial cells. Translating these insights, we evaluate next-generation therapeutic strategies aimed at this immunometabolic axis, including precision small-molecule modulators, nucleic acid-based technologies, and biologics. These approaches represent a promising strategic shift from non-specific immunosuppression toward targeted immunometabolic modulation. This synthesis provides a foundational framework for understanding SRMI and charts a roadmap for developing novel precision medicine interventions to improve patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.